Here, quality control of purified EV revealed no differences insize, total number of EVs and overall protein concentration of EVs, between CMS patients (CHRNE-, CHRNA1-, CHRNB1, CHAT-, and SLC18A3-related) and controls (Fig. 3a). This evidence concerns the gene SLC18A3 and congenital myasthenic syndrome.